Policy & Regulation
Everest Medicines announces positive topline data from multi-centre Phase three Etrasimod clinical trial in Asia
1 December 2023 - Everest Medicines (HKEX 1952.HK), a China-based biopharmaceutical company, announced on Thursday positive topline data from a multi-centre Phase three clinical trial of Etrasimod in ...
Clarity Pharmaceuticals starts registrational Phase III CLARIFY trial
1 December 2023 - Clarity Pharmaceuticals (ASX: CU6), an Australia-based, clinical stage radiopharmaceutical company, announced on Thursday that it has started its registrational Phase III 64Cu-SAR-bi...
Soligenix's Phase 2a SGX945 clinical trial IND application receives US FDA approval
1 December 2023 - Soligenix, Inc. (Nasdaq: SNGX), a US-based, late-stage biopharmaceutical company, announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) f...
SciNeuro Pharmaceuticals completes dosing in phase one SNP318 study
1 December 2023 - SciNeuro Pharmaceuticals, a China-based clinical stage biotech company developing treatments for neurodegenerative diseases, particularly Alzheimer's Disease (AD) and Parkinson&...
Calliditas Therapeutics starts phase two setanaxib clinical study
1 December 2023 - Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX), a Sweden-based commercial stage biopharma company, announced on Thursday that it has started a phase two clinical...
Johnson & Johnson MedTech acquires Laminar in USD400m deal
30 November 2023 - Johnson & Johnson MedTech, part of healthcare products company Johnson & Johnson (NYSE:JNJ), confirmed on Thursday that it has completed its acquisition of Laminar Inc, a pr...